Survival Prognosis Relevance Research For Ercc1, Rrm1Expression InⅠ～ⅢA Stage Non～mall Cell Lung Cancer

Purpose By immunohistochemical method for the detection of Ⅰ～Ⅲa stage non-small cell lung cancer tissue of patients with drug-resistant gene excision repair cross-complementing group1and Ribonucleotide Reductase M1expression, discuss ERCC1and RRM1expression on the survival prognostic implications, and provide basis for clinical treatment of clinical treatment, implementation of individualized treatment.Method75patients in Ⅰ～Ⅲa NSCLC are detected by using the SupervisionTM for ERCC1and RRM1expression. Application of the statistical software SPSS13, ERCC1,RRM1expression and clinical features are compared by using χ2test. Survival time is calculated monthly, with a confirmed diagnosis of non small cell lung cancer to death or last follow-up was censored time, the application of Kaplan-Meier method in survival analysis, using Log-rank test for difference. The application of Spearman analysises correlation, a=0.05.Result1、75NSCLC patients are measured by ERCC1expression, where ERCC1expression rate is54.6%(41/75). χ2test shows that ERCC1expression and stage、sex、age、pathological types are not correlated (P>0.05).2、75NSCLC patients are measured by RRM1expression, where RRM1expression rate is48%(36/75).χ2test showes that RRM1expression and stage、sex、age、pathological types are not correlated (P>0.05).3、ERCC1expression under clinical features and survival rate are not associated (P>0.05). the prognosis mainly relates with TNM stage and chemotherapy, comparing the median survival time. In la stage NSCLC patients, ERCC1postive expressions MST is better than negative expression, ERCC1postive expression s MST is30months, while negative expression s MST is28months (P=0.778); In Ib stage NSCLC patients, ERCC1postive expressions MST is better than negative expression, ERCC1postive expression s MST is32months, while negative expressions MST is29months (P=0.134). In Ⅱ-Ⅲa stage NSCLC patients, ERCC1postive expressions MST is close to negative expression, ERCC1postive expressions MST is28months, while negative expression s MST is29months, there is no difference in Statistics (P=0.839). In GP chemotherapy group, ERCC1postive expression s MST is26months, while negative expression s MST is32months (P=0.974); In NP chemotherapy group, ERCC1postive expressions MST is29months, while negative expression s MST is33months (P=0.121).4、RRM1expression under clinical features and survival rate are not associated (P>0.05). In Ⅰ stage NSCLC patients, RRM1postive expression can obtain the survival advantage; In Ⅱ～Ⅲa stage NSCLC patients, RRM1postive expressions MST is32months, while negative expression s MST is28months (P=0.742); In GP chemotherapy group, RRM1postive expression s MST is26months, while the RRM1negative s MST is28months (P=0.662); In NP chemotherapy group, RRM1postive expressions MST is32months, while the RRM1negative s MST is29months (P=0.904).5、Application of correlation analysis of Spearman, ERCC1and RRM1expression are positive correlated, there is statistically significant difference (r=0.251, P=0.030).Conclusion1、The expression of ERCC1and RRM1in Ⅰ～Ⅲa stage NSCLC patients were not associated with stage、gender、age、histological type. 2、Phase Ⅰ a of ERCC1、RRM1positive expression group survival is better, suggesting that the positive expression of two genes is a protective factor.3、In the Ⅰ～Ⅲa stage patients with ERCC1negative group can benefit from chemotherapy regimens containing platinum and obtain the survival advantage. RRM1negative group received GP regimen chemotherapy can obtain the survival advantage.4、In Ⅰ～Ⅲa stage NSCLC patients, the expression of ERCC1and RRM1is positively related, speculate that the expression of ERCC1and RRM1is a group of functionally related proteins.5、The results of study analysis suggests that the expression of ERCC1、RRM1positive expression in I a stage NSCLC patients can obtain good prognosis; In Ⅰ～Ⅲa stage NSCLC patients, ERCC1negative expression can benefit from chemotherapy regimens containing platinum and obtain the survival advantage, RRM1negative group can benefit from gemcitabine and obtain longer survival advantage. Thus, according to the detection of ERCC1,RRM1expression results can guide clinical individualized treatment.